Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Rivastigmine

Generic Name: Rivastigmine

Brand Names: Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₂N_₂O_₂

CAS Number: 123441-03-2

Unique Ingredient Identifier: PKI06M3IW0

Overview

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Background

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions

Dementia With Lewy Body Disease
Mild Dementia due to Parkinson's disease
Mild Dementia of the Alzheimer's Type
Moderate Alzheimer's Type Dementia
Moderate Dementia due to Parkinson's disease

Clinical Trials

Cognitive Decline in Non-demented PD

Phase 4

Completed

Posted: 2011/04/25

Sponsor:Oregon Health and Sc...

ID:NCT01340885

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

Completed

Posted: 2011/03/10

Sponsor:Seoul National Unive...

ID:NCT01312363

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

Phase 3

Completed

Posted: 2010/08/18

Sponsor:

Federal University o...

ID:NCT01183806

Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions

Phase 1

Completed

Posted: 2010/06/17

Sponsor:Dr. Reddy's Laborato...

ID:NCT01146067

Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions

Phase 1

Completed

Posted: 2010/06/17

Sponsor:Dr. Reddy's Laborato...

ID:NCT01146041

FDA Approved Products

RIVASTIGMINE TARTRATE

Manufacturer:Nivagen Pharmaceuticals, Inc.

Route:ORAL

Strength:4.5 mg in 1 1

Approved: 2017/09/06

NDC:75834-135

Rivastigmine Tartrate

Manufacturer:Alembic Pharmaceuticals Limited

Route:ORAL

Strength:4.5 mg in 1 1

Approved: 2023/01/16

NDC:46708-065

Rivastigmine

Manufacturer:Northstar Rx LLC.

Route:TRANSDERMAL

Strength:13.3 mg in 24 h

Approved: 2022/10/04

NDC:16714-117

Rivastigmine Tartrate

Manufacturer:Alembic Pharmaceuticals Inc.

Route:ORAL

Strength:3 mg in 1 1

Approved: 2022/04/07

NDC:62332-064

Rivastigmine Tartrate

Manufacturer:Breckenridge Pharmaceutical, Inc

Route:ORAL

Strength:3 mg in 1 1

Approved: 2022/04/28

NDC:51991-794

Singapore Approved Products

No Singapore products found for this drug

Related News

Japan Approves Luye Pharma's Twice-Weekly Rivastigmine Patch for Alzheimer's Disease

2 months ago

Japan's Ministry of Health, Labour and Welfare has approved Luye Pharma's innovative Rivastigmine Twice Weekly Transdermal Patch (Rivaluen® LA Patch) for mild to moderate Alzheimer's disease, marking the first extended-release rivastigmine transdermal formulation in the country.

Cholinesterase Inhibitors Show Promise in Managing Cognitive Decline in Lewy Body Dementia

7 months ago

A recent 10-year study suggests that cholinesterase inhibitors (ChEIs) may be effective in managing cognitive decline in patients with Lewy body dementia (LBD).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy